The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer.

"Conflict of interest YZ participated in advisory board for Oncohost Honorarium to Mayo Clinic. YZ has received research funding support from Mirati Therapeutics, Zai Lab, Pfizer, PDS Biotechnology, Merck & Co., Mereo BioPharma, Jacobio Pharmaceuticals, Incyte GI innovation, GenMab and AstraZeneca. RM participated in advisory board for AstraZeneca Pharmaceuticals, Novocure, Oncohostand Janssen Pharmaceutical. YL has Sebastian Szmit has received research funding support from Merck, Tolero Pharmaceuticals, AstraZeneca, Blueprint Medicines, Sun Pharma, Mirati Therapeutics, Genmab, EMD Serono, Jacobio pharma, TOPALLIAN, and Daiichi Sankyo. YL participated in advisory board for AstraZeneca Pharmaceuticals, Janssen Pharmaceutical, Lilly Oncology, Turning point therapeutics, Oncohost, and Mirati Therapeutics Honorarium to Mayo Clinic. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article."